Biomark Diagnostics Inc

STU:20B (Canada)  
€ 0.15 (+8.57%) Jul 1
At Loss
Market Cap:
€ 14.55M ($ 15.64M)
Enterprise V:
€ 15.08M ($ 16.20M)
Volume:
-
Avg Vol (2M):
2.04K
Trade In:

Business Description

Description
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.
Name Current Vs Industry Vs History
Cash-To-Debt 0.29
Equity-to-Asset -0.42
Debt-to-Equity -1.94
Debt-to-EBITDA -1.03
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -11.13
Distress
Grey
Safe
Beneish M-Score -3.33
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 84.96
9-Day RSI 65.84
14-Day RSI 56.1
6-1 Month Momentum % -25
12-1 Month Momentum % -35.26

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.28
Quick Ratio 0.28
Cash Ratio 0.23
Days Sales Outstanding 69.88

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.8
Shareholder Yield % 0.9

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -999.39
Net Margin % -937.81
FCF Margin % -572.57
ROA % -177.97
ROIC % -139.8
ROC (Joel Greenblatt) % -232.09

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 235
EV-to-EBIT -15.31
EV-to-EBITDA -21.1
EV-to-Revenue 134.93
EV-to-FCF -23.47
Earnings Yield (Greenblatt) % -6.53
FCF Yield % -4.42